Comparative Pharmacology
Head-to-head clinical analysis: ARISTOSPAN versus FLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOSPAN versus FLAC.
ARISTOSPAN vs FLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
Triamcinolone hexacetonide (Aristospan) is administered intra-articularly or intralesionally. For intra-articular use in adults, typical dose is 2–20 mg (0.5–1 mL of 20 mg/mL suspension) depending on joint size. For intralesional use, 2–3 mg per injection site, with total dose not exceeding 0.5 mg/kg per day.
Adults: 40 mg orally twice daily.
None Documented
None Documented
Triamcinolone hexacetonide: terminal half-life approximately 2-3 weeks (88-144 hours) due to slow release from depot site; clinical effects persist for weeks to months.
2-4 hours; prolonged in renal impairment (up to 12 hours)
Primarily hepatic metabolism; renal excretion of inactive metabolites (<5% unchanged); minimal biliary/fecal excretion.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Category C
Category C
Corticosteroid
Corticosteroid